Cargando…
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Massachusetts Medical Society
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722690/ https://www.ncbi.nlm.nih.gov/pubmed/33259154 http://dx.doi.org/10.1056/NEJMc2031670 |
| _version_ | 1783620204825149440 |
|---|---|
| author | Aydillo, Teresa Gonzalez-Reiche, Ana S. Aslam, Sadaf van de Guchte, Adriana Khan, Zenab Obla, Ajay Dutta, Jayeeta van Bakel, Harm Aberg, Judith García-Sastre, Adolfo Shah, Gunjan Hohl, Tobias Papanicolaou, Genovefa Perales, Miguel-Angel Sepkowitz, Kent Babady, N. Esther Kamboj, Mini |
| author_facet | Aydillo, Teresa Gonzalez-Reiche, Ana S. Aslam, Sadaf van de Guchte, Adriana Khan, Zenab Obla, Ajay Dutta, Jayeeta van Bakel, Harm Aberg, Judith García-Sastre, Adolfo Shah, Gunjan Hohl, Tobias Papanicolaou, Genovefa Perales, Miguel-Angel Sepkowitz, Kent Babady, N. Esther Kamboj, Mini |
| author_sort | Aydillo, Teresa |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7722690 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Massachusetts Medical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77226902020-12-16 Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer Aydillo, Teresa Gonzalez-Reiche, Ana S. Aslam, Sadaf van de Guchte, Adriana Khan, Zenab Obla, Ajay Dutta, Jayeeta van Bakel, Harm Aberg, Judith García-Sastre, Adolfo Shah, Gunjan Hohl, Tobias Papanicolaou, Genovefa Perales, Miguel-Angel Sepkowitz, Kent Babady, N. Esther Kamboj, Mini N Engl J Med Correspondence Massachusetts Medical Society 2020-12-01 /pmc/articles/PMC7722690/ /pubmed/33259154 http://dx.doi.org/10.1056/NEJMc2031670 Text en Copyright © 2020 Massachusetts Medical Society. All rights reserved. http://www.nejmgroup.org/legal/terms-of-use.htm This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the Covid-19 pandemic or until revoked in writing. Upon expiration of these permissions, PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
| spellingShingle | Correspondence Aydillo, Teresa Gonzalez-Reiche, Ana S. Aslam, Sadaf van de Guchte, Adriana Khan, Zenab Obla, Ajay Dutta, Jayeeta van Bakel, Harm Aberg, Judith García-Sastre, Adolfo Shah, Gunjan Hohl, Tobias Papanicolaou, Genovefa Perales, Miguel-Angel Sepkowitz, Kent Babady, N. Esther Kamboj, Mini Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title | Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title_full | Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title_fullStr | Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title_full_unstemmed | Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title_short | Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer |
| title_sort | shedding of viable sars-cov-2 after immunosuppressive therapy for cancer |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722690/ https://www.ncbi.nlm.nih.gov/pubmed/33259154 http://dx.doi.org/10.1056/NEJMc2031670 |
| work_keys_str_mv | AT aydilloteresa sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT gonzalezreicheanas sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT aslamsadaf sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT vandeguchteadriana sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT khanzenab sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT oblaajay sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT duttajayeeta sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT vanbakelharm sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT abergjudith sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT garciasastreadolfo sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT shahgunjan sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT hohltobias sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT papanicolaougenovefa sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT peralesmiguelangel sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT sepkowitzkent sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT babadynesther sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer AT kambojmini sheddingofviablesarscov2afterimmunosuppressivetherapyforcancer |